Retroviral Insertional Mutagenesis Can Contribute to Immortalization of Mature T Lymphocytes

Several cases of T-cell leukemia caused by gammaretroviral insertional mutagenesis in children treated for x-linked severe combined immunodeficiency (SCID) by transplantation of autologous gene-modified stem cells were reported. In a comparative analysis, we recently showed that mature T cells, on the contrary, are highly resistant to transformation by gammaretroviral gene transfer. In the present study, we observed immortalization of a single T-cell clone in vitro after gammaretroviral transduction of the T-cell protooncogene LMO2. This clone was CD4/CD8 double-negative, but expressed a single rearranged T-cell receptor. The clone was able to overgrow nonmanipulated competitor T-cell populations in vitro, but no tumor formation was observed after transplantation into Rag-1 deficient recipients. The retroviral integration site (RIS) was found to be near the IL2RA and IL15RA genes. As a consequence, both receptors were constitutively upregulated on the RNA and protein level and the immortalized cell clone was highly IL-2 dependent. Ectopic expression of both, the IL2RA chain and LMO2, induced long-term growth in cultured primary T cells. This study demonstrates that insertional mutagenesis can contribute to immortalization of mature T cells, although this is a rare event. Furthermore, the results show that signaling of the IL-2 receptor and the protooncogene LMO2 can act synergistically in maligniant transformation of mature T lymphocytes.

[1]  Kendall A. Smith,et al.  Interleukin-2: inception, impact, and implications. , 1988, Science.

[2]  R. V. van Lier,et al.  Regulation of CD27 expression on subsets of mature T-lymphocytes. , 1993, Journal of immunology.

[3]  F. Alt,et al.  Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. , 1995, Immunity.

[4]  T. Dassopoulos,et al.  IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. , 1998, Immunity.

[5]  J. Metcalf,et al.  Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. , 2000, Blood.

[6]  D. Scadden,et al.  Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. , 2000, Blood.

[7]  C. von Kalle,et al.  Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. , 2001, Human gene therapy.

[8]  J. Currier,et al.  Spectratype/Immunoscope Analysis of the Expressed TCR Repertoire , 2000, Current protocols in immunology.

[9]  A. Freud,et al.  Fatal leukemia in interleukin-15 transgenic mice. , 2001, Blood cells, molecules & diseases.

[10]  C. von Kalle,et al.  Murine Leukemia Induced by Retroviral Gene Marking , 2002, Science.

[11]  Takeharu Nagai,et al.  Shift anticipated in DNA microarray market , 2002, Nature Biotechnology.

[12]  D. Gilliland,et al.  Focus on acute leukemias. , 2002, Cancer cell.

[13]  William C Hahn,et al.  Rules for making human tumor cells. , 2002, The New England journal of medicine.

[14]  C. Macken,et al.  A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  C. von Kalle,et al.  Gene Therapy Targeting Hematopoietic Cells: Better Not Leave It to Chance , 2003, Acta Haematologica.

[16]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[17]  Michel Sadelain,et al.  Occurrence of leukaemia following gene therapy of X-linked SCID , 2003, Nature Reviews Cancer.

[18]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[19]  Christof von Kalle,et al.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.

[20]  Mark A Rizzo,et al.  An improved cyan fluorescent protein variant useful for FRET , 2004, Nature Biotechnology.

[21]  Thomas M. Schmitt,et al.  Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro , 2004, Nature Immunology.

[22]  J. Buckner,et al.  Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 Antibodies , 2004, Journal of immunotherapy.

[23]  A. Hotz-Wagenblatt,et al.  Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  C. von Kalle,et al.  Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. , 2005, Blood.

[25]  S. Rosenberg,et al.  Bcl-2 overexpression enhances tumor-specific T-cell survival. , 2005, Cancer research.

[26]  H. Stein,et al.  Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma , 2006, Nature Immunology.

[27]  I. Verma,et al.  Gene therapy: Therapeutic gene causing lymphoma , 2006, Nature.

[28]  C. Bordignon,et al.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[30]  K. Cornetta,et al.  Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. , 2007, Blood.

[31]  F. Bushman,et al.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.

[32]  Christine Kinnon,et al.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.

[33]  M. Hansmann,et al.  Resistance of mature T cells to oncogene transformation. , 2008, Blood.

[34]  B. Thiers.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2008 .

[35]  G. Inghirami,et al.  NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. , 2009, Cancer research.

[36]  Zhixiong Li,et al.  Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  Zongdong Li,et al.  Decitabine Increase Platelet Count by Two Mechanisms. , 2009 .

[38]  D. Laer.  Peaceful coexistence or clonal dominance , 2009 .

[39]  Hans Martin,et al.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.

[40]  Ralph Stadhouders,et al.  Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma , 2010, Nature Medicine.